The estimated Net Worth of Corinne Pankovcin is at least $506 Tisíc dollars as of 25 May 2021. Ms Pankovcin owns over 4,220 units of ADiTx Therapeutics stock worth over $55,968 and over the last 9 years she sold ADTX stock worth over $0. In addition, she makes $450,000 as Pres at ADiTx Therapeutics.
Ms has made over 3 trades of the ADiTx Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently she bought 4,220 units of ADTX stock worth $10,803 on 25 May 2021.
The largest trade she's ever made was buying 4,220 units of ADiTx Therapeutics stock on 25 May 2021 worth over $10,803. On average, Ms trades about 1,531 units every 303 days since 2015. As of 25 May 2021 she still owns at least 114,220 units of ADiTx Therapeutics stock.
You can see the complete history of Ms Pankovcin stock trades at the bottom of the page.
Corinne D. Pankovcin CPA, CPA, M.B.A. is the Pres at ADiTx Therapeutics.
As the Pres of ADiTx Therapeutics, the total compensation of Ms A at ADiTx Therapeutics is $450,000. There are 1 executives at ADiTx Therapeutics getting paid more, with Amro Albanna having the highest compensation of $1,678,060.
Ms A is 55, she's been the Pres of ADiTx Therapeutics since . There are 3 older and 8 younger executives at ADiTx Therapeutics. The oldest executive at ADiTx Therapeutics, Inc. is Dr. Joachim-Friedrich Kapp M.D., Ph.D., 79, who is the Sr. VP of Clinical Devel. - Autoimmunity.
Corinne's mailing address filed with the SEC is C/O ADITXT, INC., 737 N. FIFTH STREET, SUITE 200, RICHMOND, VA, 23219.
Over the last 4 years, insiders at ADiTx Therapeutics have traded over $691,184 worth of ADiTx Therapeutics stock and bought 24,613 units worth $89,662 . The most active insiders traders include Paribas Securities Corp Bnp, Corinne Pankovcin a Jeffrey W. Runge. On average, ADiTx Therapeutics executives and independent directors trade stock every 93 days with the average trade being worth of $2,473. The most recent stock trade was executed by Paribas Securities Corp Bnp on 6 September 2023, trading 20,800 units of ADTX stock currently worth $691,184.
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
ADiTx Therapeutics executives and other stock owners filed with the SEC include: